DRRX earnings

Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

-     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceutical co

-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis -         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design -         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026 -         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET CUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigene

CUPERTINO, Calif., Aug. 7, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its second quarter financial results on Tuesday, August 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceu

-         FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis -         Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif., May 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended March 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.

CUPERTINO, Calif., May 7, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its first quarter financial results on Monday, May 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is a late-stage biopharmaceutical

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right s

CUPERTINO, Calif., March 20, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: www.durect.com) is pio

-  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET -  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif., Nov. 13, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2023 and provided a corporate update. www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to

CUPERTINO, Calif., Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results for the three months ended June 30, 2023 on Wednesday, August 9, 2023.  Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time.  Details for the call is as follows: www

CUPERTINO, Calif., May 1, 2023 /PRNewswire/ --- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023. www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)" alt="DURECT Corporation (www.durect.com) is pioneering the development and commerci

CUPERTINO, Calif., Feb. 28, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference call after the market close on Tuesday, March 7, 2023.   Tuesday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 International: 201-689-8261 Conference ID: 13736560 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Do9m0bih   About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endog

-  Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET -  AHFIRM trial timeline continues to improve CUPERTINO, Calif., Nov. 2, 2022 /PRNewswire / -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update. "We are excited that we are now on track to complete enrollment of our pivotal AHFIRM trial in the second quarter of 2023, earlier than we previously estimated.  We continue to make excellent progress toward our goal of bringing larsucosterol to market as the first FDA-approved treatment for alcohol-associated hepatitis," stated James E. Brown, D.V.M., President and CEO of DURECT.  "In additi

CUPERTINO, Calif., Oct. 26, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the market close on Wednesday, November 2, 2022. Wednesday, November 2 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 International: 201-689-8261 Conference ID: 13733742 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=FVUpzjla   About DURECT Corporation DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous

-  Webcast of Earnings Call Today, August 4th at 4:30 p.m. ET -  Enrollment accelerating in the AHFIRM trial CUPERTINO, Calif., Aug. 4, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2022 and provided a corporate update. "We continue to see enrollment accelerating in the larsucosterol (DUR-928) AHFIRM trial and are pleased to announce that we have enrolled 170 patients to date.  The second quarter continued the recent positive enrollment trend, with more patients dosed than in any prior quarter, reflecting the opening of additional clinical trial sites and our ongoing efforts to work with existing sites to recruit m

CUPERTINO, Calif., July 27, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Thursday, August 4, 2022. Thursday, August 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free: 1-877-869-3847 International: 201-689-8261 Conference ID: 13731890 Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=oxQ1dFOB About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigeneti

- Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET - Adding new clinical sites and patient dosing progressing in the AHFIRM trial CUPERTINO, Calif., May 4, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended March 31, 2022 and provided a corporate update. "Progress continues in the larsucosterol (DUR-928) AHFIRM trial, with more patients dosed in the first quarter of 2022 than in any prior quarter, reflecting the opening of additional clinical trial sites and our ongoing efforts to work with existing sites to recruit more patients with severe alcohol-associated hepatitis (AH) that meet our enrollment criteria," stated Jame

CUPERTINO, Calif., April 27, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its first quarter 2022 financial results and host a conference call after the market close on Wednesday, May 4, 2022. Wednesday, May 4 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:                               1-800-285-6670 International:                        713-481-1320 Conference ID:                     13729654 Webcast:                               https://event.choruscall.com/mediaframe/webcast.html?webcastid=6RVdxB8I About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic live

CUPERTINO, Calif., March 7, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months and year ended December 31, 2021 and provided a corporate update. "We are pleased with the progress made over the past few months in the larsucosterol (DUR-928) AHFIRM trial, including opening international sites and the enrollment rate of patients with severe alcohol-associated hepatitis (AH)," stated James E. Brown, D.V.M., President and CEO of DURECT.  "We also signed a U.S. licensing agreement for POSIMIR® with Innocoll Pharmaceuticals and look forward to their anticipated launch in the second quarter of 2022." Fourth Quarter and Recent Business Highlig

CUPERTINO, Calif., Feb. 28, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its fourth quarter and full year 2021 financial results and host a conference call after the market close on Monday, March 7, 2022. Monday, March 7 @ 4:30pm Eastern Time / 1:30pm Pacific Time Toll Free:                877-869-3847 International:          201-689-8261 Conference ID:      13727525 Webcast:                https://themediaframe.com/mediaframe/webcast.html?webcastid=qrEvoVo0 About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesa

CUPERTINO, Calif. and ATHLONE, Ireland, Dec. 22, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR® (bupivacaine solution) for infiltration use, DURECT's FDA-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the United States. "We are excited to license the U.S. development and commercialization rights for POSIMIR to Innocoll, whose dedicated hospital sale

CUPERTINO, Calif., Nov. 2, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2021 and provided a corporate update. "I am proud of the progress we have made in expanding clinical trial sites and the pace of enrollment in the AHFIRM study, particularly given the challenges faced by many of the hospitals where our study is being conducted in dealing with the Delta variant surge."  stated James E. Brown, DVM, President and CEO of DURECT. "I am also pleased with the progress made in our POSIMIR licensing process." Third Quarter and Recent Business Highlights: Continued progress in clinical study site openings – DURECT

CUPERTINO, Calif., Oct. 26, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its third quarter 2021 financial results and host a conference call after the market close on Tuesday, November 2, 2021. www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. (PRNewsFoto)" alt="DURECT Corporation (www.durect.com) is pioneering the development and c

CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update. Q2 2021 Accomplishments: We expanded the number of U.S. clinical trial sites to 26 in the Phase 2b AHFIRM clinical study of DUR-928 in severe alcohol-associated hepatitis (AH), and we are enrolling at a good rate. We have now opened about 75% of the U.S. sites we plan to open. We expect to open our first ex-U.S. clinical sites (in the UK, Europe and Australia) in the coming months. In addition, we presented further encouraging DUR-928 clinical data from the completed NASH Phase 1b trial showing trends for

CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021. Thursday, July 29 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 201-689-8560 Conference ID: 13721980 Webcast: http://public.viavid.com/index.php?id=145979 About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DU